ASCO Experts Update Guidance for Sacituzumab Govitecan (Trodelvy®) for HR+, HER2- MBC - Metastatic Breast Cancer Trial Talk

From the Experts

In 2021, sacituzumab govitecan (Trodelvy®) was approved by the FDA to treat people with triple-negative MBC. In February 2023, the FDA expanded the approval of the drug for people with HR+, HER2- MBC who have received at least two lines of therapy. As a result, the American Society of Clinical Onoclogy (ASCO) also updated its guidance on the use of this drug.

Read below for more information about this new approval and comments from MBC experts.

Introduction to Sacituzumab Govitecan (Trodelvy®)
Sacituzumab Govitecan (Trodelvy®) for HR+, HER2- MBC
Sacituzumab Govitecan (Trodelvy®) for Triple-Negative MBC
Clinical Trials for Sacituzumab Govitecan (Trodelvy®)

Last Modified on September 26, 2023



for past articles or specific information.